OncoCare is pleased to share that Dr. Peter Teo, clinical oncologist, was invited by the Hong Kong Society of Clinical Oncology (HKSCO) to participate as a panelist at two clinical knowledge exchange meetings held in early July. Both events focused on the latest developments in the treatment of non-small cell lung cancer (NSCLC), bringing together oncology and respiratory medicine specialists, etc. from across Hong Kong to discuss evolving treatment strategies and patient care.
As a clinical oncology specialist with experience in NSCLC treatment, Dr. Peter Teo joined fellow medical professionals to share his clinical insights on emerging therapies, treatment selection, and patient-centred decision-making.
Moving Beyond Monotherapy in EGFR-Mutated NSCLC
The first meeting, with a panel discussion themed "How to Move Beyond Monotherapy?", focused on the changing treatment landscape for patients with EGFR-mutated NSCLC. The event attracted more than 80 clinical oncologists, medical oncologists, and respiratory medicine specialists interested in the latest advances in targeted lung cancer therapies.
Moderated by Dr. Molly Li, the panel included Dr. Daniel Lui, Professor James Ho, Professor Sum Min Lim, and Dr. Peter Teo. Together, they discussed which patient groups may benefit from treatment approaches beyond monotherapy, factors influencing treatment selection, and the importance of helping patients make informed treatment decisions through effective doctor-patient communication.
The session generated active discussion among both panel members and attendees, reflecting growing interest in personalised treatment strategies for EGFR-mutated NSCLC.
Advancing Second-Line and Beyond Treatment Strategies in HER2-Mutant NSCLC
The second meeting, with a panel discussion of "Advancing 2L+ Treatment Strategies in HER2-Mutant NSCLC", explored the latest clinical developments for patients whose disease has progressed beyond first-line treatment.
Moderated by Professor Tony Mok, the expert panel featured Dr. Ernest Nadal, Dr. Oscar Chan, Dr. Jeffery Wong, and Dr. Peter Teo. The discussion focused on the evolving treatment landscape for HER2-mutant NSCLC, current challenges in later-line treatment settings, emerging clinical evidence, and practical considerations for optimising patient outcomes.
The event was attended by more than 100 healthcare professionals and encouraged meaningful exchanges between the expert faculty and participants.
Advancing Lung Cancer Care Through Clinical Exchange
Both meetings fostered insightful discussions and active audience participation, highlighting the importance of scientific collaboration in advancing lung cancer care.
Through engagements such as these, Dr. Peter Teo continues to contribute to the development of evidence-based NSCLC treatment in Hong Kong by sharing clinical expertise and participating in professional dialogue that helps shape contemporary oncology practice.
At OncoCare, we remain committed to supporting continuous medical education, scientific collaboration, and precision oncology to help ensure patients have access to the most appropriate and effective cancer treatments available.






